Litigation Details for Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc. (D. Del. 2020)
✉ Email this page to a colleague
Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc. (D. Del. 2020)
| Docket | ⤷ Try a Trial | Date Filed | 2020-03-26 |
| Court | District Court, D. Delaware | Date Terminated | 2022-08-10 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | ALVOGEN PB RESEARCH AND DEVELOPMENT LLC | ||
| Patents | 10,314,828; 10,335,397; 10,456,384; 6,861,053; 7,045,620; 7,417,042; 7,612,199; 7,737,112; 7,902,206; 7,906,542; 7,915,275; 7,928,115; 8,158,644; 8,158,781; 8,193,196; 8,207,125; 8,309,569; 8,518,949; 8,642,573; 8,741,904; 8,829,017; 8,835,452; 8,853,231; 8,946,252; 8,969,398; 9,023,001; 9,023,417; 9,271,968; 9,421,195; 9,623,001; 9,629,828 | ||
| Attorneys | Ricardo S. Camposanto | ||
| Firms | JPMorgan Chase & Co. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals, Inc. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-03-26 | 1 | Complaint | (the “’9,828 patent”); 10,314,828 (the “’4,828 patent”); 10,335,397 (the “’397 patent”); and 10,456,…; 8,969,398; 9,271,968; 9,421,195; 9,629,828; 10,314,828; 10,335,397; and 10,456,384 by submitting ANDA…; 8,969,398; 9,271,968; 9,421,195; 9,629,828; 10,314,828; 10,335,397; and 10,456,384 under 35 U.S.C. … 8,969,398; 9,271,968; 9,421,195; 9,629,828; 10,314,828; 10,335,397; and 10,456,384 remain valid and … 8,969,398; 9,271,968; 9,421,195; 9,629,828; 10,314,828; 10,335,397; and 10,456,384, inclusive of any | External link to document |
| 2021-08-03 | 118 | Notice of Service | the Invalidity of U.S. Patent Nos. 8,642,573; 8,969,398; 9,421,195; 10,335,397; and 10,709,694 4. Opening…Bergstrom, Ph.D. Regarding the Invalidity of U.S. Patent No. 7,906,542 2. Opening Expert of Michael J. Zaworotko…Zaworotko, Ph.D. Regarding the Invalidity of U.S. Patent Nos. 7,045,620; 7,612,199; 7,902,206; and 7,906,542…2020 10 August 2022 1:20-cv-00430 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-10-19 | 138 | Notice of Service | Ph.D. Regarding the Invalidity of U.S. Patent Nos. 7,045,620; 7,612,199; 7,902,206; and 7,906,542 (3)…Bergstrom, Ph.D. Regarding the Invalidity of U.S. Patent No. 7,906,542 (7) Responsive Expert Report of Richard…Regarding Noninfringement of Claims 9 and 10 of U.S. Patent No. 7,906,542 filed by Norwich Pharmaceuticals …2020 10 August 2022 1:20-cv-00430 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
